canagliflozin + cyclosporine

**Canagliflozin + cyclosporine** is an unbranded combination of two small-molecule drugs. Canagliflozin is a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor used for the treatment of type 2 diabetes mellitus; it increases urinary glucose excretion by inhibiting reabsorption of filtered glucose in the proximal renal tubule. Cyclosporine is an immunosuppressant agent, primarily a calcineurin inhibitor, that prevents T-cell activation and cytokine production and is used mainly in transplantation and autoimmune disease. The combination does not represent a marketed fixed-dose formulation but refers to coadministration of the two agents. Co-administration has been studied: cyclosporine increases canagliflozin exposure (AUC) by about 23% via P-glycoprotein inhibition, but this does not result in clinically meaningful interactions, and no dose adjustments are required. Each agent retains its individual mechanism of action, and the combination is typically used only in clinical or special pharmacokinetic contexts, not as a fixed product.[1][3][4]